Literature DB >> 10842181

The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1.

G Fuh1, K C Garcia, A M de Vos.   

Abstract

Neuropilin-1 (NP-1) was first identified as a semaphorin receptor involved in neuron guidance. Subsequent studies demonstrated that NP-1 also binds an isoform of vascular endothelial growth factor (VEGF) as well as several VEGF homologs, suggesting that NP-1 may also function in angiogenesis. Here we report in vitro binding experiments that shed light on the interaction between VEGF165 and NP-1, as well as a previously unknown interaction between NP-1 and one of the VEGF receptor tyrosine kinases, VEGFR1 or Flt-1. BIAcore analysis demonstrated that, with the extracellular domain (ECD) of NP-1 immobilized at low density, VEGF165 bound with low affinity (K(d) = 2 microm) and fast kinetics. The interaction was dependent on the heparin-binding domain of VEGF165 and increased the affinity of VEGF165 for its signaling receptor VEGFR2 or kinase insert domain-containing receptor. The affinity of VEGF165 for the NP-1 ECD was greatly enhanced either by increasing the density of immobilized NP-1 (K(d) = 113 nm) or by the addition of heparin (K(d) = 25 nm). We attribute these affinity enhancements to avidity effects mediated by the bivalent VEGF165 homodimer or multivalent heparin. We also show that the NP-1 ECD binds with high affinity (K(d) = 1.8 nm) to domains 3 and 4 of Flt-1 and that this interaction inhibits the binding of NP-1 to VEGF165. Based on these results, we propose that NP-1 acts as a coreceptor for various ligands and that these functions are dependent on the density of NP-1 on the cell membrane. Furthermore, Flt-1 may function as a negative regulator of angiogenesis by competing for NP-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842181     DOI: 10.1074/jbc.M003955200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

Review 1.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

3.  Peptide-targeted, stimuli-responsive polymersomes for delivering a cancer stemness inhibitor to cancer stem cell microtumors.

Authors:  Fataneh Karandish; James Froberg; Pawel Borowicz; John C Wilkinson; Yongki Choi; Sanku Mallik
Journal:  Colloids Surf B Biointerfaces       Date:  2017-12-24       Impact factor: 5.268

4.  Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin.

Authors:  Matthew W Parker; Lance M Hellman; Ping Xu; Michael G Fried; Craig W Vander Kooi
Journal:  Biochemistry       Date:  2010-05-18       Impact factor: 3.162

5.  VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 6.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

7.  Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Authors:  Sophia Ran; Xianming Huang; Amber Downes; Philip E Thorpe
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

8.  Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding.

Authors:  Brent A Appleton; Ping Wu; Janice Maloney; JianPing Yin; Wei-Ching Liang; Scott Stawicki; Kyle Mortara; Krista K Bowman; J Michael Elliott; William Desmarais; J Fernando Bazan; Anil Bagri; Marc Tessier-Lavigne; Alexander W Koch; Yan Wu; Ryan J Watts; Christian Wiesmann
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

9.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

10.  Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  Physiol Genomics       Date:  2009-04-07       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.